Kiora Pharmaceuticals Receives IND Approval for Phase 2 Study of KIO-101 for Ocular Autoimmune Disease

KIORA PHARMACEUTICALS INC

Kiora received IND approval from FDA for Phase 2 study of KIO-101 for ocular surface disease in autoimmune patients.
Phase 2 trial will enroll ~120 patients in a multi-center, randomized, double-masked, controlled study assessing safety and efficacy.
Study expected to begin enrolling patients in Australia in first half of 2023; two concentrations (0.15% and 0.30%) will be tested.
KIO-101 is a topical DHODH inhibitor; systemic DHODH inhibitors generate ~$2B annually; target market ~3.43M U.S. patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.